Drugs / bersacapavir
bersacapavir
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04853524 | May → Jun 2021 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT04474210 | Aug → Nov 2020 | impaired renal function disease | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04208399 | Jan 2020 → Mar 2021 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1 | NCT03945539 | May → Oct 2019 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1 | NCT03864601 | Apr → Jun 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02933580 | Oct 2016 → Feb 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02662712 | Dec 2015 → Jun 2018 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03365947 | Mar 2018 → Apr 2020 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04439539 | Sep 2020 → Aug 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04129554 | Nov 2019 → Jul 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03982186 | Aug 2019 → Mar 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03361956 | Feb 2018 → Sep 2019 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03111511 Background | Mar → Aug 2017 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04585789 Background | Mar 2021 → Feb 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bersacapavir | “JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV replication.” PMID 37442152 ↗ Jul 20231“JNJ-56136379 (JNJ-6379; bersacapavir)” PMID 38583491 ↗ Apr 2024 |
| Known as | JNJ 56136379 | “Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single...” NCT03945539 ↗ |
| Known as | JNJ-6379 | “This phase IIa trial (ClinicalTrials.gov Identifier: NCT03365947) assessed the safety and efficacy of the small-interfering RNA JNJ-73763989 (JNJ-3989) plus a nucleos(t)ide...” PMID 35870702 ↗ Jul 20223“JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV replication.” PMID 37442152 ↗ Jul 2023 “JNJ-56136379 (JNJ-6379), a capsid assembly modulator” PMID 32343960 ↗ Apr 2020 “JNJ-56136379 (JNJ-6379; bersacapavir)” PMID 38583491 ↗ Apr 2024 |
| Action | Inhibit | “JNJ-6379 specifically and potently inhibited HBV replication” PMID 32094138 ↗ Apr 2020 |
| Modality | Other / unclassified | “JNJ-56136379 (JNJ-6379), a capsid assembly modulator” PMID 32343960 ↗ Apr 2020 |
| Route | Oral | “JNJ-56136379 oral tablets will be given” NCT02662712 ↗ |